NewAmsterdam Pharma Completes Enrollment In Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease
Portfolio Pulse from Happy Mohamed
NewAmsterdam Pharma (NASDAQ:NAMS) has completed patient enrollment in the Phase 3 BROADWAY clinical trial evaluating obicetrapib, a non-statin medicine for patients at high risk of cardiovascular disease. The trial exceeded its target enrollment of 2,400 subjects due to strong interest, with over 2,500 patients expected to be randomized. Topline data is expected in the second half of 2024. The trial aims to evaluate the effect of obicetrapib on LDL-C levels and other lipid parameters predictive of cardiovascular disease risk.
July 25, 2023 | 8:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NewAmsterdam Pharma has completed enrollment for its Phase 3 BROADWAY trial of obicetrapib. The trial exceeded its target enrollment, indicating strong interest in the drug. Topline data is expected in 2H 2024.
The completion of enrollment for the Phase 3 trial indicates progress in the development of obicetrapib. The strong interest in the trial suggests a potential demand for the drug once it is approved and commercialized. This could have a positive impact on NewAmsterdam's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100